- Amended Statement of Ownership (SC 13G/A)
2012年2月15日 - 6:21AM
Edgar (US Regulatory)
SCHEDULE 13G
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
YM Biosciences, Inc.
(Name of Issuer)
Common Stock, No Par Value
|
(Title of Class of Securities)
984238105
|
|
(CUSIP Number)
December 31, 2011
|
|
|
(Date of Event which Requires Filing
of this Statement)
|
|
Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:
*The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover
page.
The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of
the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act,
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No.
984238105
1
|
NAMES
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
Felix J. Baker
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP (See Instructions)
(a)
£
(b)
£
|
3
|
SEC
USE ONLY
|
4
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
United States
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE
VOTING POWER
-0-
|
6
|
SHARED
VOTING POWER
8,865,657
|
7
|
SOLE
DISPOSITIVE POWER
-0-
|
8
|
SHARED
DISPOSITIVE POWER
8,865,657
|
9
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,865,657
|
10
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
£
|
11
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.5%
|
12
|
TYPE OF REPORTING
PERSON (See Instructions)
IN
|
|
|
|
|
CUSIP No.
984238105
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
Julian C. Baker
|
2
|
CHECK THE APPROPRIATE BOX IF A
MEMBER OF A GROUP (See Instructions)
(a)
£
(b)
£
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
-0-
|
6
|
SHARED VOTING POWER
8,865,657
|
7
|
SOLE DISPOSITIVE POWER
-0-
|
8
|
SHARED DISPOSITIVE POWER
8,865,657
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,865,657
|
10
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
£
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.5%
|
12
|
TYPE OF REPORTING
PERSON (See Instructions)
IN
|
|
|
|
|
|
|
Item 1(a)
|
Name of
Issuer:
|
YM Biosciences
|
Item 1(b)
|
Address
of Issuer’s Principal Executive Offices:
|
5045 Orbiter Drive
Building 11, Suite 400
Mississauga,
Ontario L4W 4Y4
|
Item
2(a)
|
Name of Person Filing:
|
|
|
|
|
|
This Schedule 13G is
being filed jointly by Felix J. Baker and Julian C. Baker (the “Reporting Persons”).
|
|
Item
2(b)
|
Address of Principal Business Office or,
if None, Residence:
|
Name
|
Business Address
|
Felix J. Baker
|
667 Madison Avenue
New York, NY 10065
|
Julian C. Baker
|
667 Madison Avenue
New York, NY 10065
|
Each of the Reporting
Persons is a United States citizen.
|
Item 2(d)
|
Title of Class of Securities:
|
Common Stock, no
par value
984238105
|
Item 3.
|
If
this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a: N/A
|
(a) [ ] Broker or
dealer registered under Section 15 of the Exchange Act.
(b) [ ] Bank as
defined in section 3(a)(6) of the Exchange Act.
(c) [ ] Insurance
company as defined in section 3(a)(19) of the Exchange Act.
(d) [ ] Investment
company registered under section 8 of the Investment Company Act of 1940.
(e) [ ] An investment
adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f) [ ] An employee
benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g) [ ] A parent
holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h) [ ] A savings
association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i) [ ] A church
plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
(j) [ ] Group, in
accordance with Rule 13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Set forth in the
table below is the aggregate number of shares of Common Stock beneficially owned along with shares of Common Stock that may be
acquired upon the exercise of Warrants as of the date hereof by each of the following, together with the percentage of outstanding
shares of Common Stock that such number represents based upon
116,711,448
shares outstanding,
as reported on the company’s SEC Form 6K filed on February 9, 2012.
Such percentage figures are calculated on the basis that the Warrants owned by the Reporting Persons are deemed exercised for shares
of Common Stock but other outstanding Warrants are not deemed converted or exercised.
Name
|
|
Number of Shares
|
|
|
Percent of Class
Outstanding
|
|
Baker Bros. Investments II, L.P.
|
|
|
1,117
|
|
|
|
0.0
|
%
|
667, L.P.
|
|
|
498,831
|
|
|
|
0.4
|
%
|
Baker Brothers Life Sciences, L.P.
|
|
|
8,126,935
|
|
|
|
6.9
|
%
|
14159, L.P.
|
|
|
227,534
|
|
|
|
0.2
|
%
|
Baker/Tisch Investments, L.P.
|
|
|
11,240
|
|
|
|
0.0
|
%
|
Total
|
|
|
8,865,657
|
|
|
|
7.5
|
%
|
By virtue of their ownership of entities
that have the power to control the investment decisions of the limited partnerships listed in the table above, Felix J. Baker and
Julian C. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power
to vote or direct the vote of and shared power to dispose or direct the disposition of such securities.
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact that
as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities,
check the following [ ]. N/A
Item 6. Ownership of More than Five Percent on Behalf
of Another Person.
The entities listed
in Item 4 above are investment funds the investors in which have the right to receive dividends, interest and the proceeds of sale
of securities owned by such funds.
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding
Company or Control Person.
|
N/A
|
Item 8.
|
Identification and Classification of Members of the Group.
|
N/A
|
Item 9.
|
Notice of Dissolution of Group.
|
N/A
By signing below
I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable
inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true,
complete and correct.
February 14, 2012
/s/ Felix J. Baker
|
Felix J. Baker
|
|
|
/s/ Julian C. Baker
|
Julian C. Baker
|
|
|
|
AGREEMENT
In accordance with
Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on
Schedule 13G relating to the Common Stock of YM Biosciences, Inc. is being filed with the Securities and Exchange Commission
on behalf of each of them.
February 14, 2012
/s/ Felix J. Baker
|
Felix J. Baker
|
|
|
/s/ Julian C. Baker
|
Julian C. Baker
|
|
YM Biosciences (AMEX:YMI)
過去 株価チャート
から 6 2024 まで 7 2024
YM Biosciences (AMEX:YMI)
過去 株価チャート
から 7 2023 まで 7 2024